• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Myocardial ischemia with no obstructive coronary arteries (INOCA) is a chronic coronary
syndrome condition that is increasingly being recognized as a substantial contributor to …

Heart failure with preserved ejection fraction (HFpEF) currently accounts for approximately
half of all new heart failure cases in the community. HFpEF is closely associated with chronic …

Heart failure demographics have evolved in past decades with the development of improved
diagnostics, therapies, and prevention. Cardiac magnetic resonance (CMR) has developed …

Coronary microvascular dysfunction (CMD) plays a crucial role across the spectrum of heart
failure (HF) pathology, contributing to disease development, progression, and outcomes …

Aims Several mechanisms have been identified in the aetiopathogenesis of heart failure
with preserved ejection fraction (HFpEF). Among these, coronary microvascular dysfunction …

Background The prognostic impact of coronary microvascular dysfunction (CMD) has been
scarcely addressed in heart failure with preserved ejection fraction (HFpEF). This study …

To date, studies on the prevalence of coronary microvascular dysfunction (CMD) in heart
failure with preserved ejection fraction (HFpEF) have not been summarized and analyzed as …

CMD-HFpEF is a prevalent endotype of HFpEF and one that is associated with adverse
cardiovascular prognosis. Whether CMD leads to HFpEF, through subendocardial …

Objectives Heart failure with preserved ejection fraction (HFpEF) is a syndrome with
significant clinical heterogeneity. Myocardial fibrosis has been considered a common …